ASND
Ascendis Pharma A/S (ASND)
Healthcare • NASDAQ • $238.66-3.04%
- Symbol
- ASND
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $238.66
- Daily Change
- -3.04%
- Market Cap
- $14.74B
- Trailing P/E
- 26.82
- Forward P/E
- 20.65
- 52W High
- $250.74
- 52W Low
- $150.89
- Analyst Target
- $296.48
- Dividend Yield
- N/A
- Beta
- N/A
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Company websiteResearch ASND on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.